+
+
Stay Informed
STRUCTURAL INTERVENTIONS

AMPLATZER™ TALISMAN™
PFO OCCLUDER

Effective PFO closure is made easier with the Amplatzer Talisman PFO Occluder.1 For patients who have experienced a PFO-associated stroke, clinical trials have shown that they can benefit from PFO closure.2-4 This minimally-invasive procedure significantly reduces the risk of recurrent ischemic stroke and offers an excellent safety profile.

THE PIONEER 
IN PFO CLOSURE1

As the device that created the category, the Amplatzer™ PFO Occluder has sustained leadership over decades of use by pursuing clinical evidence to become the first device supported by positive PFO trial results.2

Today, it is the most-studied device of its kind, with over 180,000 patients treated worldwide.1 And our clinical evidence is unmatched, thanks to the largest-ever trial for PFO closure, boasting 5,810 patient-years of data.2

Amplatzer PFO Occluder is the first device supported by positive patent foramen ovale trial results

About the Amplatzer Talisman
PFO Occluder

With the Amplatzer Talisman PFO Occluder, the device you know and trust just got better. It is built on the proven Amplatzer PFO closure technology and the Amplatzer Trevisio™ Delivery System, with key enhancements to make it our most advanced and easy-to-use PFO closure device yet:

  • The occluder comes assembled and ready to use, simplifying preparation and enhancing ease-of-use
  • We re-engineered the 30mm size with a smaller left atrial disc to better avoid interference with surrounding structures

The PFO Occluder trusted by thousands of physicians around the world1

180K+

Global implants1


WE SET THE STANDARD

  • Pioneered treatment with a PFO-specific device
  • Available in over 80 countries around the world

5,810

PATIENT-YEARS OF DATA2


WE RAISE THE BAR

  • With the landmark RESPECT trial,2 we had the most extensive patient follow-up, almost 2x more than other PFO trials
  • RESPECT was also the only trial to include patients on anticoagulation therapy, a real-world cross-section of patients

990

PATIENTS IMPLANTED WITH DEVICE IN RCTS2-4


WE DEMONSTRATE EXCELLENCE

  • ZERO device erosions, thrombus, or embolization events in 6 published trials with 990 patients
  • 94.2% effective closure rate at 6 months

How to implant the Amplatzer Talisman 
PFO Occluder

Watch the Amplatzer Talisman PFO Occluder implant procedure video.

The Amplatzer Talisman PFO Occluder is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients who have had an ischemic stroke due to a presumed paradoxical embolism.

Among patients with a PFO who have had an ischemic stroke, the Amplatzer Talisman PFO Occluder has demonstrated excellent safety and effectiveness in reducing the risk of recurrent stroke.

Key benefits for PFO patients

59% RELATIVE RISK REDUCTION IN RECURRENT ISCHEMIC STROKE5

LESS ANXIETY, MORE PEACE-OF-MIND

For patients who have experienced a PFO-associated stroke, the thought of a recurrence can generate anxiety. Determining and delivering the most effective treatment soon after a stroke is critically important to provide these patients with peace-of-mind.

For patients and caregivers wanting to learn more about PFO-associated stroke and PFO closure, www.PFOstroke.com is an excellent resource, including:

  • All about PFO and stroke
  • Understanding PFO treatment options
  • Information about PFO occluders
  • Resources, including FAQ and brochures
     

Back to walking 12 miles per day

Alan Butcher - England

As an employee of the Royal Mail postal service “I’m back on full delivery, walking nearly 12 miles a day. Now it gets to be 8:00 at night, and I’m still bouncing off the walls, full of energy. I feel that I owe everyone who was involved a massive thank you.”

FEATURES

Advancing the Gold Standard in PFO Closure

For decades, interventional cardiologists have trusted the Amplatzer PFO Occluder for ease-of-use, safety, and excellent clinical outcomes.2 With our latest addition, the Amplatzer Talisman PFO Occlusion System, the easy-to-use just got easier:

  • The occluder comes assembled and ready to use, streamlining preparation and enhancing the user experience.

  • We've refined the 30mm size with a smaller left atrial disc to better avoid interference with surrounding structures

Amplatzer PFO Occlusion System features pre-attached occluder and re-designed hemostasis valve

Often Imitated,
Never Matched

Unique design features set the Amplatzer Talisman PFO Occluder apart from the rest.

Often Imitated, Never Matched

*Only the 18 mm size is not asymmetric.
†Effective closure.

Amplatzer PFO Occluder demonstrated over 94 percent closure rate in clinical trial

Minimizing Complexity in PFO Closure

SIMPLIFIED
PREP

Occluder comes assembled to the flexible Trevisio™ delivery cable, ready to use

Amplatzer PFO Occluder comes assembled to Trevisio delivery cable, ready to use

RECAPTURABLE AND REPOSITIONABLE

Self-expanding discs align to the PFO without an additional “locking” step and can be adjusted for ideal placement
 

Amplatzer PFO Occluder is recapturable and repositionable for better PFO closure

LOW-PROFILE
DELIVERY

8 F and 9 F introducer sheaths enable treatment of patients with smaller vasculature

Amplatzer PFO Occluder offers options for patients with smaller vasculature
Abbott Amplatzer Portfolio App helps physicians determine which structural intervention device to use


GET THE AMPLATZER PORTFOLIO APP

The Amplatzer Portfolio App helps physicians determine which Amplatzer Structural Interventions device to use by suggesting applicable devices based on respective Instructions for Use.
 

App Store
Google Play

MAT-2010605 v6.0 | Item approved for OUS use only.

References
  1. Data on file at Abbott.
  2. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022-1032. doi: 10.1056/NEJMoa1610057.
  3. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377:1033-1042. doi: 10.1056/NEJMoa1707404.
  4. Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011-1021 and supplementary appendix. doi: 10.1056/NEJMoa1705915.
  5. Messé SR, Gronseth GS, Kent DM, et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020;94(20):876-885. doi:10.1212/WNL.0000000000009443
Abbott Logo

Follow Abbott

Copyright © 2024 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: Product(s) are intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use, inside the product carton (when available) or at www.eifu.abbott for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v18.0 | Item approved for OUS use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. Health Care Professionals International Health Care Professionals

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+